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Abstract
Background: Blood pressure, lipid, and glycemic control are essential for reducing cardiovascular disease (CVD) risk.
Many health care systems have successfully shifted aspects of chronic disease management, including population-
based outreach programs designed to address CVD risk factor control, to non-physicians. The purpose of this study
is to evaluate provision of new information to non-physician outreach teams on need for treatment intensification
in patients with increased CVD risk.
Methods: Cluster randomized trial (July 1-December 31, 2008) in Kaiser Permanente Northern California registry of
members with diabetes mellitus, prior CVD diagnoses and/or chronic kidney disease who were high-priority for
treatment intensification: blood pressure≥140 mmHg systolic, LDL-cholesterol≥130 mg/dl, or hemoglobin
A1c≥9%; adherent to current medications; no recent treatment intensification). Randomization units were medical
center-based outreach teams (4 intervention; 4 control). For intervention teams, priority flags for intensification were
added monthly to the registry database with recommended next pharmacotherapeutic steps for each eligible
patient. Control teams used the same database without this information. Outcomes included 3-month rates of
treatment intensification and risk factor levels during follow-up.
Results: Baseline risk factor control rates were high (82-90%). In eligible patients, the intervention was associated
with significantly greater 3-month intensification rates for blood pressure (34.1 vs. 30.6%) and LDL-cholesterol (28.0
vs 22.7%), but not A1c. No effects on risk factors were observed at 3 months or 12 months follow-up. Intervention
teams initiated outreach for only 45-47% of high-priority patients, but also for 27-30% of lower-priority patients.
Teams reported difficulties adapting prior outreach strategies to incorporate the new information.
Conclusions: Information enhancement did not improve risk factor control compared to existing outreach
strategies at control centers. Familiarity with prior, relatively successful strategies likely reduced uptake of the
innovation and its potential for success at intervention centers.
Trial registration: ClinicalTrials.gov Identifier NCT00517686
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Blood pressure, lipid, and glycemic control are essential
for reducing cardiovascular disease (CVD) risk. [1-7] Al-
though control of these conditions is improving nationally,
[8-12] large proportions of patients remain suboptimally
controlled. Non-adherence to prescribed medications is
one reason for poor control. [13-15] “Clinical inertia,” or
failure to advance pharmacotherapy in persons adhering
to current medications, is another. [13,16-24]
Many health care systems have shifted aspects of
chronic disease management to non-physicians with posi-
tive results for risk factor control. [25-28] Using treatment
algorithms and electronic health information, pharmacists,
nurses, or medical assistants can support patient self-
management and advance evidence-based pharmacother-
apy in collaboration with physicians.
In this translational study, we evaluated an enhance-
ment of medical information used by non-physician out-
reach staff to further improve treatment intensification
in patients at risk for CVD, who were adherent to
current medications but with elevated blood pressure,
LDL-cholesterol, and/or hemoglobin A1c values.
Methods
This six-month intervention (July 1 - December 31, 2008)
used a cluster randomized controlled design among enrol-
lees of Kaiser Permanente Northern California (KPNC).
The unit of randomization was KPNC medical center-
based, non-physician, population management outreach
teams (n=8). KPNC is an integrated health care system
providing comprehensive care to over 3.2 million enrollees
through 21 medical centers. KPNC’s Institutional Review
Board approved this study, waiving the requirement for
individual informed consent because the intervention
represented an enhancement to usual population-based
outreach care.
Study population
The KPNC PHASE (Preventing Heart Attacks and Strokes
Everyday) population registry was identified in 2005 for a
management program aimed at preventing CVD. [29] The
registry is refreshed monthly and includes approximately
300,000 KPNC members, ages 18–85, at increased CVD
risk because of: diabetes mellitus (DM); prior diagnoses of
coronary artery disease, cerebrovascular disease, periph-
eral artery disease or abdominal aortic aneurysm; and/or
advanced chronic kidney disease (age≥50 and GFR<30
or GFR <60 with proteinuria).
Medical center-based PHASE outreach teams are com-
posed of a varying mix of clinical pharmacists, registered
nurses, and medical assistants across centers. Teams
conduct mail and telephone outreach to improve use of
recommended medications and risk factor control. PHASE
guidelines provide general evidence-based therapeutic
algithms for achieving targets for blood pressure <130/
80 mmHg for patients with DM or CKD <75 years, <140/
90 mmHg for all others; LDL-cholesterol (LDL-c)
<100 mg/dL; and hemoglobin A1c (A1c) <7.0%. For
patients with prior CVD, aspirin (≥81 mg daily), a statin
(≥40 mg simvastatin or equivalent daily), and an ACE-
inhibitor (≥lisinopril 10 mg daily or equivalent) are recom-
mended. For those with only DM, a statin from age 40, an
ACE-inhibitor from age 55, and aspirin from age 50 in men
and age 60 in women are recommended.
All teams use the Population Management Tool (PMT),
a web-enabled database, to identify and track PHASE
patients. The PMT presents risk factor and medication in-
formation that is refreshed weekly and accessible through
standard queries. Some centers focus exclusively on reach-
ing quality targets; others outreach to all patients periodic-
ally. Teams communicate with primary care physicians via
the electronic health record, secure e-mail and telephone.
Center-level performance for risk factor control and
use of recommended medications is monitored quar-
terly. Performance targets are one component of modest
center-directed incentive payments[30].
Identifying eligibility for treatment intensification
Within the PHASE population, risk factor levels and recent
prescription fills were monitored monthly during the inter-
vention to identify persons newly eligible for treatment in-
tensification. The first search used a 3-month look-back
window. Eligibility required: 1) most recent risk factor
levels (systolic blood pressure (SBP), A1c, or LDL-c) above
target (2 consecutive elevated values were required for
SBP; 2)≥7 months prior continuous KPNC enrollment to
measure adherence and prior treatment intensification;
3) adherence to previously prescribed medications for the
condition; and 4) no treatment intensification for the con-
dition in the prior month. Blood pressures from inpatient,
emergency, or procedure-related visits were not used to
identify eligibility or assess effectiveness.
Adherence was measured separately for each condition
by averaging adherence estimates across all condition-
related medications in the period from 6 months before
the elevated risk factor was noted to the date of the subse-
quent monthly data pull. For each medication, total days
between the first prescription in this period and the data
pull were summed and proportions of those days with
available medications calculated. An average medication
possession ratio was calculated across all condition-
related medications. To account for stockpiling, remaining
days supply from prior prescriptions for the same medica-
tion were added to numerators. Hospital days were sub-
tracted from both numerators and denominators. Persons
with average medication ratios of≥80% were considered
adherent and therefore eligible for treatment intensifica-
tion. Patients on insulin but no oral diabetes medications
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cause insulin adherence and treatment intensification are
difficult to measure.
Randomization, training and intervention process
The study concept was presented to PHASE team lea-
ders in late 2007, along with data on the relationship of
treatment intensification to improved risk factor control.
[12] Leaders from nine out of a total of 17 center service
areas expressed interest in participating. During the first
6 months of 2008, researchers met regularly with re-
gional and center-based PHASE leadership to refine the
study information to be placed in the PMT. In June,
medical centers were randomized after blocking on cen-
ter population size and current rates of treatment in-
tensification. The small number of centers precluded
additional blocking. Five centers were randomized to the
intervention, four to the control arm. Before the inter-
vention began, one intervention team underwent major
re-organization and withdrew from the study. This left a
total of 8 centers available for randomization.
Because of concern that staff might be unable to out-
reach to all eligible patients in a timely way, the study
investigators and PHASE operations team leaders par-
ticipating in the study created a prioritization scheme
based on risk factor levels: Priority 1: SBP≥140 mmHg;
Priority 2: LDL-c≥130 mg/dL; Priority 3: A1c≥9%; Pri-
ority 4: SBP 130–139 mmHg in persons with diabetes or
CKD; Priority 5: LDL-c 100–129 mg/dL; Priority 6: A1c
7–8.9%. For Priority 1, members≤85 years were flagged.
For other priorities, the upper age limit was 75. Staff at
intervention centers agreed to process those in priorities
1–3 first. During the intervention, priority flags (up to 3
per patient), along with PHASE-recommended next
steps in pharmacotherapy for each individual patient for
use at the point-of-care, were prominently placed into
the PMT and refreshed monthly. PHASE teams partici-
pating in the study were trained in the use of the new
flags, and PHASE center leaders were provided with
periodic feedback on how many eligible patients were
being processed.
Qualitatitive interviews
Qualitative pre- and post-intervention interviews with
intervention team leaders at each center assessed goals,
structure, and tactics of each center’s program, and
recorded experiences and barriers encountered in using
the new information. These interviews were conducted
in the 2 months prior to the scheduled start of the inter-
vention, and again after the intervention had ended. The
baseline interview included domains to assess existing
population care-based approaches to adherence and
treatment intensification; staffing levels; and use of the
PMT in existing PHASE program structure. The follow-
up interviews included domains to assess changes in the
population care programs as a result of the intervention;
experience with the intervention; and barriers and facili-
tators to the intervention’s implementation at each site.
In addition, researchers met monthly with intervention
team leaders during the study to support use of the new
information. The PMT was modified to allow interven-
tion staff to record dates and types of processing efforts
(e.g. review, outreach).
Analyses
Analyses were conducted separately by priority. Primary
analyses considered Priorities 1–3. We excluded PHASE
patients who did not have a KPNC pharmacy benefit and
those in long-term care. Outcomes were receipt of treat-
ment intensification within 3 months after placing an eli-
gibility flag in the PMT (baseline), and changes in risk
factor levels during 12 months post-baseline. Treatment
intensification was defined as filling a prescription for a
medication class not used in the prior 7 months or an in-
crease in prescribed dosage of a current medication. Sec-
ondary analyses examined rates of intensification within
6 months and compared rates between intervention center
patients processed by the outreach team and those not
processed.
We used first recorded risk factor values at least 3 months
post-baseline to assess mean risk factor change; we
included all values for the entire 12-month post-baseline
period in a repeated measures analyses. Although early
post-baseline values in these analyses could precede treat-
ment intensification, we included them because early values
showing a return to control would be a reason not to order
another test for some time. Small percentages of patients
with no follow-up values of SBP, LDL-c, or A1c (3%; 14%,
10% respectively) were not included in analyses. Although
we did not expect that treatment intensification or risk fac-
tor control would improve for priorities 4–6, we analysed
these priorities in secondary analyses. We also compared
proportions of patients “in control” during follow-up using
priority-specific cutpoints in repeated measures analyses.
Persons with missing values post-baseline were alternately
treated as “not in control” or excluded. Finally, we com-
pared control for the entire PHASE populations using last
recorded values at 12 months after the intervention began.
Hierarchical logistic regression models (SAS PROC
MIXED with GLIMMIX Macro) were used to compare
treatment intensification rates, adjusting for patient age,
sex, race/ethnicity, risk factor level and number of medi-
cations at baseline. Hierarchical linear regression models
(SAS PROC MIXED) with an autoregressive covariance
structure were used for repeated measures analyses of
risk factor endpoints. A covariate for time from baseline
to each measurement, and random effects for center,
were included in all models.
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study power to detect follow-up risk factor differences as-
suming 8 centers, 4 in each arm; 2300 eligible patients per
center for blood pressure and LDL-c; 1700 for A1c con-
trol; average of 6 post-intervention blood pressure mea-
sures, one LDL-c and one A1c measure during 12-months
follow-up. Intra-class correlations for centers were 0.01
for SBP, 0.006 for LDL-c, and 0.008 for A1c [31] . Simula-
tions indicated 80% power to detect intervention-control
differences of 3.4 mmHg for SBP; 6.7 mg/dL for LDL-c;
0.42% for A1c. The subsequent decision to focus only on
patients in the top 3 priorities reduced eventual sample
sizes by more than 50% for each risk factor, but focused
on patients with most room for improvement.
Results
Of 188,781 total PHASE patients at participating centers,
11.6% were excluded because of age (n=13,705), lack of a
pharmacy benefit (n=5,215), or residence in long-term
care on July 1, 2008 (n=3,069) (Figure 1). Of remaining
patients, 18.6% of intervention center patients and 20.3% of
control center patients met intensification criteria for at
least one risk factor, and were also adherent to their medi-
cations for blood pressure (64% adherent), cholesterol (69%
adherent) or diabetes (67% adherent) at some point during
the 6-month intervention. Approximately 7% of subjects
were subsequently excluded because of disenrollment or
loss of a drug benefit; moving to a non-study medical cen-
ter for primary care; or death in the first six months of
follow-up. Among remaining eligible patients, fewer than
half fell into the higher priorities 1–3 in each arm.
Intervention center patients were slightly older, less
likely to be female, and much more likely to be white
(62.0 vs. 44.4%) than control center patients (Table 1).
Patients from control centers used slightly more blood
pressure medications at baseline. Prevalence of PHASE-
qualifying co-morbidities and smoking were similar. For
the entire PHASE populations at these centers, control
rates at baseline were high, especially for the levels of
Priorities 1–3. Control was slightly better at intervention
than control sites for SBP <140 mmHg but differed little
for other priorities.
(N=166,792)
Center randomization
Intervention Centers
(N=95,355)
Control Centers
N=71,437
4 
Centers
4 
Centers
Priority 1
SBP ≥ 140
3080 (3.2%)
Priority 2
LDL-C ≥ 130
2431 (2.5%)
Priority 4
SBP ≥ 130
3878 (4.1%)
Priority 3
A1c ≥ 9%
1318 (1.4%)
Priority 5
LDL-c ≥ 100
4876 (5.1%)
Priority 6
A1c 7-8.9%
3750 (3.9%)
Priority 1
SBP ≥ 140
2905 (4.1%)
Priority 2
LDL-C ≥ 130
1789 (2.5%)
Priority 3
A1c ≥ 9%
1059 (1.5%)
Priority 6
A1c 7-8.9%
3007 (4.2%)
Priority 5
LDL-c ≥100
3526 (4.9%)
Priority 4
SBP ≥ 130
3583 (5.0%)
Exclusions
(N=21,989)
Age<18 or >85
In SNF or hospice
No drug benefit
8 KPNC Centers
Total Phase Patients: 
(N=188,781)
Lost to Follow-
up in <6 mos
N=1119 ( 6.3%)
Disenrolled or 
dropped drug 
benefit:              711  
Moved to non-
study center      179
Death                229
Met at least one
eligibility criterion
(n= 14,535, 20.3%)
Met at least one
eligibility criterion
(N=17,703, 18.6%)
Lost to Follow-
up in <6 mos
N=1112 ( 7.7%)
Disenrolled or 
Dropped drug
benefit:               727  
Moved to non-
study center       219
Death                 166
N=16,584 N=13,423
Figure 1 Flow sheet for cluster randomized trial showing total numbers of PHASE patients at participating medical centers, exclusions
by reason, and final numbers of patients eligible at some time during the six-month intervention in each of six risk factor-based
priority levels.
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Treatment intensification within 3 months of eligibility
was modestly but significantly more likely at interven-
tion centers for Priority 1 (34.1 vs. 30.6%) and Priority 2
(28.0 vs. 22.7%) (Table 2). By six months, these differ-
ences had decreased and were not statistically significant
(Priority 1: 47.2 vs.0 44.9%; Priority 2: 37.0 vs. 34.1%).
Differences in treatment intensification for Priority 3
and for Priorities 4–6 were smaller and non-significant.
Adjustment for baseline demographics, blood pressure
or LDL-c values, and numbers of medications did not
reduce the magnitude of either difference (33.4% vs.
29.4% for Priority 1; 31.5% vs 25.4% for Priority 2).
Risk factor levels
Baseline risk factor levels were similar and post-baseline
declines substantial at intervention and control sites, espe-
cially for Priority 1–3. No intervention-control site differ-
ences in adjusted risk factor levels were observed during
follow-up (Table 2). The largest effect was seen for Priority
2, where intervention group subjects had adjusted LDL-c
levels 2.6 mg/dL lower than control group subjects. In
Table 1 Characteristics of Eligible Patient Population, Study vs. Control Sites
STUDY (n=16,584) CONTROL (n=13,423) P-Value
Mean Age (yrs) 61 60 <.0001
% Female 49.9 51.8 <.0001
Race/Ethnicity (%)
Asian/PI 9.0 12.3 <.0001
Black 6.1 16.2 <.0001
Hispanic 9.8 12.6 <.0001
Native American 1.3 1.3 0.97
White 62.0 44.4 <.0001
Other/Multiple 2.9 2.2 <.0001
Missing Race 8.9 11.0 <.0001
Comorbidities
Mean Number of Comorbidities* 1.23 1.25 0.01
Has Diabetes (%) 77.5 80.4 <.0001
Current Smoker (%) 8.9 9.0 0.77
Mean Risk Factor Values at Baseline**
Systolic Blood Pressure (mm Hg) 131 132 0.18
LDL-cholesterol (mg/dL) 100 98 <0.001
Hemoglobin A1c (%) 7.3 7.3 0.13
Mean # Medication Classes, Baseline
Blood Pressure Medications 1.74 1.82 <.0001
Diabetes Medications 1.22 1.23 0.19
Dyslipidemia Medications 0.70 0.70 0.35
On Max Med Therapy at Baseline (%)
Simvastatin/Atorvastatin 80 mg 12.3 13.8 <.0001
3 or more Blood Pressure Meds 27.8 31.0 <.0001
Insulin, if has diabetes 20.0 20.5 0.38
Baseline control rates (%) Entire PHASE Populations - by priority level
Priority 1: SBP <140 mmHg 83.5 81.8
Priority 4: SBP <130 mmHg 61.1 60.7
Priority 2: LDL-c <130 mg/dL 90.2 90.2
Priority 5: LDL-c <100 mg/dL 71.8 71.7
Priority 3: A1c <9% 90.3 90.9
Priority 6: A1c <7% 60.5 60.0
*Comorbidity count based on whether patient is flagged in the Population Management Tool as being in these populations: abdominal aortic aneurism, coronary
artery disease, chronic kidney disease, diabetes, peripheral artery disease, and cerebrovascular disease.
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Patients, by Priority Level
Study (n=4 sites) Control (n=4 sites)
Priority Number
Eligible
Patients
Intensified
within
3 months
Baseline
Mean Risk Factor
Level
†
Unadjusted
Risk Factor
Decline
{
Number
Eligible
Patients
Intensified
within
3 months
Baseline
Mean Risk
Factor Level
†
Unadjusted
Risk Factor
Decline
{
Adjusted Study-Control
Risk Factor Differences
(95% CI)
}
1: SBP≥140 3,080 34.1
€ 153.2 13.6 2,905 30.6
€ 153.0 13.4 0.73
(-1.40, 2.83)
2: LDL-c≥130 2,431 28.0
€ 153.1 24.9 1,789 22.7
€ 153.9 23.8 -2.63
(-6.73, 1.48)
3: A1c≥9% 1,318 29.5 10.2 1.0 1,059 28.8 10.2 1.2 -0.02
(-0.36, 0.32)
4:SBP 130-139
£ 3,878 22.9 138.5 6.0 3,583 22.0 138.5 5.0 -0.00
(-1.25, 1.26)
5: LDL-c 100-129 4,876 20.5 111.4 10.1 3,526 19.1 111.3 8.9 -0.83
(-4.10, 2.44)
6. A1c 7-8.9% 3,750 26.3 7.5 0 3,007 26.9 7.5 0 0.03
(-0.10, 0.16)
† Based on the last value recorded before follow-up begins; i.e., the value that qualified patient for treatment intensification.
{ Based on the first value recorded after 3 months follow-up; if no values recorded between 3 and 12 months follow-up, the latest value recorded during first 3 months follow-up was used. No values were available
during follow-up for 3%, 10%, and 14% of blood pressure, A1c, and LDL-c tests, respectively.
} From repeated measures models using all available values during follow-up,with adjustment for age, gender, race-ethnicity, baseline risk factor value, number of medications for the risk factor at baseline, and days
of follow-up at time of each measurement. Negative value indicates that the adjusted difference favored the study group group during follow-up.
€ p<0.001 for study vs. control comparison.
£ Only patients with diabetes mellitus and/or chronic kidney disease were eligible for the target of SBP <130 mmHg.
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3adjustment models for Priorities 2 and 3, addition of an in-
dicator for treatment intensification within 3 months
yielded large, statistically significant associations of treat-
ment intensification with lower follow-up LDL-c and A1c
levels. In contrast, receiving treatment intensification for
SBP (Priority 1) was associated with significantly higher SBP
values at follow-up, suggesting that, for blood pressure, in-
tensification may have been reserved for those whose high
SBP persisted through the early weeks of follow-up (rather
than regressing to an earlier mean). After adjustment for
baseline rates of treatment intensification, there was no evi-
dence that the intervention led to greater heterogeneity in
intensification rates than that seen among control centers.
Secondary analyses of proportions reaching control
showed similarly small, non-significant differences for
Priorities 1 and 2, whether patients with no follow-up
values were treated as “not in control” or excluded. Over
50% or patients in each arm reached control. For priority
3, patients at control sites were more likely to be in con-
trol at follow-up (52.2% vs. 46.6%). This differences was
somewhat smaller and no longer significant in the
repeated measures analysis (4.9 mmHg, p=0.22).
Impact of intervention processing
Outreach staff at intervention sites initiated processing
within 3 months for only 45 to 47% of patients in Priorities
1–3 (Table 3). Despite the intervention plan to process
higher priority patients first, processing was also begun for
27 to 29% of patients in priorities 4–6. In each priority,
treatment intensification was more frequent in patients for
whom processing was begun. Differences were greatest for
Priorities 2 and 5 (LDL-c control).
Baseline risk factor levels were similar between those
who were processed and remaining patients. Processing
was not associated with significant differences in risk
factor declines during follow-up. For LDL-c, declines
were slightly greater in those processed, but for SBP and
A1C the converse was true.
Control in entire phase populations
Control improved modestly in both intervention and
control centers in the entire PHASE population for all
priorities except Priority 6, where proportions with A1C
<7% declined slightly for each group (Table 4). Changes
were nearly identical for intervention and control popu-
lations for all priorities.
Qualitative interviews with intervention site coordinators
All 4 intervention sites reported some continued pursuit of
previous strategies that addressed risk factor control targets
in all patients, without respect to study prioritization or ad-
herence information. Staff reported feeling a need to
Table 3 Treatment Intensification Rates, Baseline Risk Factor Levels, Declines and Adjusted Mean Differences During
Follow-up - Processed vs. Not Processed Patients, Intervention Centers Only, by Priority Level
Processed Not Processed
Priority Percent
Processed
†
Intensified
within 3 mos (%)
Baseline Mean
Risk Factor
Level
{
Unadjusted
Decline
}
Intensified
within
3 mos (%)
Baseline Mean
Risk Factor
Level
{
Unadjusted
Decline
}
Adjusted Difference
(Processed – not
Processed) During
Follow-up (95% CI)
€
1: SBP≥140 mmHg 45 40.5 153.4 13.1 28.8 153.0 14.1 1.01
(0.30, 1.75)
2: LDL-c≥130 mg/dL 46 36.3 152.8 25.9 21.0 153.4 24.0 -0.6
(-3.4, 2.2)
3: A1c≥9% 47 32.6 10.3 1.0 26.7 10.2 1.0 -0.03
(-0.19, 0.14)
4:SBP 130-139
£ 29 27.4 138.9 5.6 21.1 138.4 6.2 1.06
(0.44, 1.69)
5: LDL-c 100-129 mg/dL 30 29.2 111.2 10.4 16.8 111.4 10.0 0.63
(-0.95, 2.22)
6. A1c 7-8.9% 28 28.9 7.6 -0.1 25.3 7.5 -0.1 -0.03
(-0.09, 0.04)
† Processed: Record review and outreach initiated by staff in response to identification of eligibility for treatment intensification.
{ Based on the last value recorded before follow-up begins; i.e., the value that qualified patient for treatment intensification.
} Based on the first value recorded after 3 months follow-up; if no values recorded between 3 and 12 months follow-up, the latest value recorded during first
3 months follow-up was used.
€ From repeated measures models using all available values during follow-up,with adjustment for age, gender, race-ethnicity, baseline risk factor value, number
of medications for the risk factor at baseline, and days of follow-up at time of each measurement. Negative value indicates that the adjusted values were lower in
the processed group during follow-up.
£ Only patients with diabetes mellitus and/or chronic kidney disease were eligible for the target of SBP <130 mmHg.
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covered the entire PHASE population of patients not cur-
rently in control. Two sites felt that the monthly PMT up-
date was not timely enough and that staff were sometimes
frustrated to find that treatment intensification had already
been initiated by primary care physicians. The other two
sites interpreted the same experience differently, suggesting
that flags be placed in the PMT only after eligible patients
had not received treatment intensification for three
months, thereby focusing efforts on the smaller group in
whom primary care appeared to have failed.
Some sites indicated that focusing on adherent patients,
rather than all with poor control, was confusing. However,
all 4 sites expressed interest both continuing to receive
the treatment intensification information and also in re-
ceiving quantitative adherence information, believing both
to be useful in working with patients not in control.
Discussion
Meaningful use of electronic health information is a sub-
ject of ongoing study. We sought to reduce clinical inertia
and enhance the efficiency of outreach efforts in the con-
text of a successful population management program by
focusing attention more closely on patients most likely to
benefit from treatment intensification. The intervention
added no new resources to clinical or outreach teams.
This translational intervention had at most a modest
impact on likelihood of prompt treatment intensification,
and for only two of three priority groups (hypertension
and hyperlipidemia). It did not lead to improvements in
risk factor levels compared to strategies already in place.
Several prior studies of computerized reminders directed
to physicians have yielded similar findings of improved
care processes with little or no impact on risk factor levels
[32-37], although one recent study did find positive results
[38]. This may be the first report of use of such reminders
for non-physician team members.
Within KPNC, risk factor control has improved stead-
ily [12,30,31] likely due in substantial part to innovations
in informatics and population management. Better-than-
expected control rates at baseline and the decision to re-
strict the target population to patients with higher risk
factor levels reduced sample size dramatically compared
to that anticipated. More than 80% of all PHASE
patients had blood pressures below the cutpoint for Pri-
ority 1 and over 90% were in control for Priorities 2 and
3 at baseline. Moreover, the small remaining proportions
with poor control may be resistant to usual population
management efforts, may have refused treatment in-
tensification previously or been judged inappropriate for
further intensification.
Despite reducing the target population, intervention
outreach staff processed only 45-47% of high-priority
patients, while also contacting 27-30% of lower-priority
patients. Coupled with qualitative reports of difficulty in-
tegrating the new information into ongoing outreach and
the need to achieve risk factor control for the population
as a whole to achieve performance targets, these findings
suggest that the context of an established, successful out-
reach program may have hindered full adoption. However,
limited evidence suggested that if all patients had been
processed, improvement in risk factor levels may have
been seen, at least for lipid-lowering therapy.
Study limitations include the small numbers of medical
centers randomized, making it impossible to block
r a n d o m i z a t i o no nm o r et h a n2v a r i a b l e s .C o n s e q u e n t l y ,
some variables, including race/ethnicity, were not balanced.
In addition, we were not able to measure socioeconomic
s t a t u so ru s et h i sv a r i a b l et ob l a n c er a n d o m i z a t i o no ra d -
just the analysis. However, analyses adjusted for race/ethni-
city, as well as for differences in baseline risk factor levels
and numbers of medications used.
The study intervention had more limited reach than
anticipated: teams were only able to reach less than half
Table 4 Pre- and Post-Intervention Risk Factor Control Rates for Entire Phase Populations, by Study Arm and Priority
Level
Study Facilities (n=4) Control Facilities (n=4)
PHASE Population
Size
1
Pre-Intervention % in
Control
2
Post-Intervention, % in
Control
2
PHASE Population
Size
1
Pre-Intervention % in
Control
2
Post- Intervention % in
Control
2
SBP≥140 72,895 83.5 84.0 54,652 81.7 82.4
LDL-c≥130 67,099 90.2 91.5 49,355 90.1 91.4
A1c≥9% 48,464 90.9 91.0 38,497 90.3 90.7
SBP 130-139
}
72,895 61.1 62.8 54,652 60.7 62.6
LDL-c 100-
129
67,099 71.8 75.3 49,355 71.7 75.5
A1c 7-8.9% 48,464 60.5 58.8 38,497 60.0 58.1
1 Members identified in Kaiser Permanente Northern California’s PHASE population from 1 year prior to the intervention to 1 year following the intervention,
eligible for the priority by virtue of age and comorbidities, and with at least one risk factor measure in each period.
2 Control assessed based on latest recorded factor value during each period.
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lect detailed information on the processes teams used to
contact patients (e.g. number of calls per patient). In
addition, results from the qualitative interviews sug-
gested that the information provided in the intervention
may have been more useful if delivered more often
than monthly. If the intervention had been more suc-
cessful in reaching all targeted patients, and/or provided
more timely updates, it is possible that we would have
observed more favorable results.
Electronic health record and automated pharmacy data
were used to determine adherence and intensification in
this study, and due to the large volume of patients
included in the intervention we were not able to validate
this information via chart review, or to therefore include
insulin adherence for diabetes patients. This potentially
may have led to biases; however, many studies in this
setting have relied on adherence and intensification in-
formation based on chart review and validated their rela-
tionship with CVD intermediate outcomes [12,13].
This study occurred in an integrated delivery system
with high baseline control rates for CVD risk factors and
well-developed non-physician population management
outreach strategies. Findings may not generalize to other
settings with lower baseline control rates or those employ-
ing different types of quality improvement strategies,
where a similar intervention may have been more (or less)
successful.
Conclusion
In summary, enhanced information on need for treatment
intensification did not improve risk factor levels in this
population. High baseline control rates and a decision to
narrow the target population limited the number of
patients who could benefit from the intervention. Inad-
equate implementation further limited detectability of any
potential benefits. Nonetheless, it is important to note that
at study conclusion, outreach staff asked to continue re-
ceiving the new information, augmented by quantitative
estimates of recent medication adherence for all patients.
Future research should continue to focus on furthering
our understanding of how to best integrated health IT
tools into population management strategies to enhance
the quality of care for patients with chronic conditions.
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